A stem cell treatment for heart failure patients is safe and shows early signs of effectiveness, according to a study published Wednesday.
The study was conducted by Japanese researchers in 27 patients, who received transplants of stem cells taken from their own thigh muscles. There were no major complications, and most patients showed considerable improvement in their symptoms.
The study was published in the open-access Journal of the American Heart Association. Dr Yoshiki Sawa of Osaka University Graduate School of Medicine was the senior author. It can be found at j.mp/stemheart.
However, two San Diego cardiologists who do stem cell research on heart disease cautioned that similar clinical trials have shown promise over the years, only to fail at the end for various reasons. There is no approved stem cell therapy for heart failure.
So while the trial itself appears to be well-conducted, the researchers are very far from actually proving their treatment is effective, said Dr. Richard Schatz of Scripps Health and Dr. Eric Adler of UC San Diego School of Medicine.
For one thing, the trial was small, they said, and larger trials are where the most rigorous scientific evaluations are made.
These early trials have looked beneficial in the past, Adler said. When we do the larger trials, the results are more equivocal.
Adler said the signs of efficacy in this trial are modest. For example, the change in ejection fraction, a measurement of efficiency in pumping blood, rose from 27 percent to 30 percent in 15 of the 27 patients. Their heart failure was associated with a lack of blood flow, or ischemia. The remaining non-ischemic patients actually had a slight decline.
The entire field of stem cell and regenerative therapy for heart disease has been a disappointment to date, Schatz said.
Weve been at it for 20 years now, and we dont have a product or a positive (late-stage) trial, so that tells you pretty much everything you need to know, he said. Its not for lack of trying or billions of dollars invested. Its just very, very difficult.
The cardiac field has had more success with other technologies, such as cardiac stents. Schatz is the co-inventor of the first stent.
In the study, the researchers acknowledge that previous attempts had only been modestly effective. They devised a method of producing sheets of muscle stem cells and attaching them to the inner layer of the sac that encloses the heart, a layer that rests directly on the heart surface.
The stem cell sheets stimulate healing by producing chemicals that stimulate cardiac regeneration, the study said. The cells themselves dont survive in the long term, but by the time they die they have served their purpose.
Loss of function
Heart failure is a progressive disease in which the heart gradually loses its ability to pump blood. This can be triggered by a heart attack or any other cause that damages the heart muscle.
When damaged heart muscle is replaced with scar tissue, as often happens, the heart loses pumping capacity. It becomes overstressed, and its output of blood declines. This limits the patients ability to engage in intensive physical activity. In advanced cases, patients may become bedridden.
Existing treatments include drugs and LVAD units, which take over some of the hearts function to relieve stress. Some drugs may help the heart work more efficiently, but none have been shown to improve heart failure by actually regenerating lost heart muscle.
Stem cell therapy is tested in patients who havent responded well to other treatments. Trials have been and are being conducted in San Diego area hospitals.
Scripps Health has been testing a cardiac stem cell therapy from Los Angeles-based Capricor. The cells, taken from donor hearts, are injected into the coronary artery, where they are expected to settle in the heart and encourage regrowth.
UC San Diego is testing a heart failure therapy from Teva Pharmaceutical Industries. It consists of bone marrow derived mesenchymal precursor cells. These can give rise to several different cell types, including muscle cells.
And many other trials are going on throughout the country and internationally.
Adler and Schatz said theres reason for optimism in the long run, as technologies improve.
Just because the other trials have been negative doesnt mean this technique wont be beneficial, Adler said. Its just too early to tell.
That said, Schatz emphasized that the nature of the three-phase clinical trial process means that the show-stoppers for a treatment typically appear late.
Tighter standards needed
Clean trials trials where we all agree that this is the patient population we want to look at, are needed, he said.
For example, heart failure comes in two types, he said. Ischemic heart failure is caused by heart attacks and blocked arteries, which impede blood flow. Non-ischemic heart failure can be caused by damage from diseases, such as a virus.
Non-ischemics can be younger people, in their 20s and 30s, while the ischemic patients are older. Mixing those patient groups in a single trial is a mistake, he said.
Theyre different animals, Schatz said.
Another pitfall is failing to screen carefully enough to enroll only patients likely to benefit, Schatz said.
You can have a patient who has chest pain, and coronary disease just incidentally, he said.
His shoulder or chest pain is from a virus. So he goes into the trial and gets a placebo injection in his arm of cortisone, and his arm pain goes away. And because hes in that placebo group, hes counted as a success the pain went away. It has nothing to do with his heart. Thats an extreme example, but we actually saw that happen.
In a failed gene therapy trial for heart disease, some patients apparently had received the injection in the wrong location, missing the heart muscle, Schatz said.
You assume they got the gene, but they didnt, Schatz said. The study was negative, and thats why I think it was negative.
Such errors dont show up in Phase 1 trials, Adler and Schatz said, because theyre focused on evaluating safety. And these early trials dont have many patients, there arent enough to comfortably determine the therapy is really effective.
By the last stage of the trial, these sources of error have often been identified and trial standards have tightened up. And thats when the faulty assumptions made early appear as the trial ends in failure.
Despite those forbidding hurdles, Adler said research should continue.
This disease is killing a lot of people. Theres not going to be enough hearts to go around for transplant. Theres six million Americans with heart failure, and theres 2,000 heart transplants a year. So coming up with novel regenerative cell-based therapy is something were still excited about.
bradley.fikes@sduniontribune.com
(619) 293-1020
Originally posted here:
Study: heart failure stem cell therapy safe, shows early signs of effectiveness - The San Diego Union-Tribune
- Revolutionizing medicine: recent developments and future prospects in ... - December 28th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 28th, 2024
- The therapeutic potential of stem cells - PMC - December 19th, 2024
- Researchers find success with stem cell therapy in mice model of ... - December 19th, 2024
- Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene ... - December 19th, 2024
- Study finds stem cell therapy is safe and may benefit people with ... - October 22nd, 2024
- Stem Cell Therapy Market Size to Hit USD 48.89 Billion by 2033 - GlobeNewswire - October 22nd, 2024
- Eves dream to walk: Family raising vital funds for two-year-olds stem cell therapy - Her.ie - October 22nd, 2024
- Stem cell therapies for chronic obstructive pulmonary disease ... - September 21st, 2024
- Magellan Stem Cells welcomes $7 million federal government grant - September 21st, 2024
- Stem Cell Therapy Research: Creative Biolabs Advances iPSC-Derived Macrophage Solutions - openPR - September 21st, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 21st, 2024
- Stem cells: Therapy, controversy, and research - Medical News Today - September 4th, 2024
- Stem cell-based therapy for human diseases - PMC - September 4th, 2024
- Bone marrow mesenchymal stem cells in treatment of peripheral nerve ... - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 5th, 2024
- Putting Stem Cell-Based Therapies in Context | National Institutes of ... - April 8th, 2024
- Eggs from men, sperm from women: Stem cell therapy may just turn reproduction upside down! - The Economic Times - January 17th, 2024
- Stem Cell Therapy: From Idea to Clinical Practice - PMC - December 13th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 18th, 2023
- Stem Cell Therapy Is It Right for You? Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy | Mellon Center Approach | Cleveland Clinic - January 31st, 2023
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - December 3rd, 2022
- Canine Stem Cell Therapy Market Size 2022 with a CAGR of % Market Share, prime companies report covers, world business Trends, Statistics, Definition,... - June 16th, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 16th, 2022
- Sutton boy pledges to raise money to help his brother with autism go to America for stem cell therapy - Mansfield and Ashfield Chad - June 16th, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 16th, 2022
- Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01 - Yahoo Finance - June 16th, 2022
- Stem cell therapy shows promise in aiding equine wound healing - Horsetalk.co.nz - Horsetalk - April 2nd, 2022
- Rheumatoid Arthritis Stem Cell Therapy Market Assessment, With Major Top Companies Analysis, Geographic Analysis, Growing Opportunities Data By... - April 2nd, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 2nd, 2022
- Talaris therapy ends need for immune drugs in transplant patients - - pharmaphorum - November 7th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 4th, 2021
- Multiple myeloma stem cell transplant: What happens and more? - Medical News Today - August 4th, 2021
- Animal Stem Cell Therapy Market Research 2021-2027 With Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, US Stem Cell The Manomet Current - The... - August 4th, 2021
- Global Stem Cell Therapy Market to witness exponential proliferation during 2020-2026 The Manomet Current - The Manomet Current - August 4th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 26 Sports - 2x6 Sports - July 21st, 2021
- NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire - June 24th, 2021
- Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,... - June 24th, 2021
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene... - June 24th, 2021
- Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire - June 24th, 2021
- Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert - March 3rd, 2021
- Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian - March 3rd, 2021
- Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering - March 3rd, 2021
- NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com - March 3rd, 2021
- Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News - March 3rd, 2021
- We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT - March 3rd, 2021
- Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -... - March 3rd, 2021
- Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU... - March 3rd, 2021
- Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The... - March 3rd, 2021
- Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv... - March 3rd, 2021
- Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance - Magazine of Santa Clarita - March 3rd, 2021
- Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY... - March 3rd, 2021
- Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The... - March 3rd, 2021
- Exclusive Insights on Stem Cell Therapy for Multiple Sclerosis Market 2021-2026: Latest Trends, Drivers, Strategies and Competitive Landscape The... - March 3rd, 2021
- Stem Cell Therapy Market By Treatment,Application,End Users And Geography Forecast To 2027 The Bisouv Network - The Bisouv Network - March 3rd, 2021
- 10 Best Clinics for Stem Cell Therapy in Thailand [2021 ... - February 14th, 2021
- Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung... - February 14th, 2021
- Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning... - February 14th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 14th, 2021
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2025 FLA... - February 14th, 2021
- Dancing on Ice's Colin Jackson to get stem cell op as he's got 'knees of 85-year-old' - Mirror Online - February 1st, 2021
- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell... - January 31st, 2021
- ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web - January 31st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - January 31st, 2021
- ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -... - January 31st, 2021
- Stem Cell Therapy for Diabetes and Related Conditions Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2025 - AlgosOnline - January 31st, 2021
- Stem Cell Therapy Market 2021 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2026 NeighborWebSJ - NeighborWebSJ - January 31st, 2021
- Animal Stem Cell Therapy Market to witness high growth in near future - Fractovia News - January 31st, 2021
- Regenerative medicine is advancing health care in diverse ways - Hometown Focus - January 23rd, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace - January 23rd, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 23rd, 2021